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Patients and methods
A retrospective study was undertaken to evaluate the results
of therapy, especially its toxicity, in view of the anticipated
long survival of patients.
The median age of patients was 63 years; age distribution is
. shown in Fig. 1. Further patient characteristics and the method
of diagnosis is shown in Table 11. The majority of patients












TABLE I. STAGING SYSTEM FOR CARCINOMA OF
THE PROSTATE
Stage Indications
A1 Clinically occult, focus well differentiated
A2 Clinically occult, diffuse or poorly differentiated
B Palpable tumour confined within prostatic capsule
C1 Palpable tumour extending beyond the prostatic capsule
C2 Massive extraprostatic tumour involving pelvic sidewall,
bladder or rectal mucosa
01 Regional lymph node metastases
02 Skeletal/visceral metastases and distant lymph node
metastases
Ninety-three patients, who were treated primarily with irradia-
tion at our institutions in the lO-year period 1979 - 1988, were
reviewed. An additional 13 patients, who had previously been
treated by hormones for at least 2 months and who were
subsequently irradiated, are also discussed (see 'Results').
All patients were staged8 (Table I) by clinical examination,
12-channel investigations, measurement of serum acid phos-
phatase levels, chest radiography and a bone scan. In more
recent years, patients have also undergone pelvic computed
tomography (CT) scans to evaluate pelvic adenopathy and
serum prostatic antigen level determination.
Carcinoma of the prostate is the second most common carci-
noma in Western countries. l Its incidence is low in Third-
World populations living traditionally but increases with
urbanisation and increased socio-economic status. 1 The defmi-
tive treatment of localised disease began in the first decade of
this century when radical prostatectomy was performed by
Young2 in the USA. Long-term disease-free survival was
obtained, but the side-effects were considerable - impotence
in nearly all patients and urinary incontinence in many, so that
the operation never became popular outside a few centres.
Patients were generally either followed up only or, after the
introduction of androgen ablation in the 194Os,3 treated pallia-
tively by orchidectomy and/or oestrogens.
In the 1960s Bagshaw' showed that treating localised pro-
static carcinoma with external beam irradiation could result in
high local control rates with relatively low morbidity. This wa~
confirmed by other studies in the 1970s.5- 7 Radical irradiation
for carcinoma of the prostate began at the joint radiotherapy
service of Groote Schuur Hospital, Cape Town; Provincial
Hospital, Port Elizabeth; and Frere Hospital, East London, in
1979.
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Summary
Ninety-three patients treated by radical irradiation for stage
A2, Band C1 carcinoma of the prostate between 1979 and
1988 at a joint radiotherapy service were reviewed. The
average age was 63 years, 84% of the patients were white
and on histological examination the tumours were well or
moderately differentiated in 88% of cases. Treatment was
with 5 fractions per week in 71% while the remainder received
3 - 4 fractions per week. At a median follow-up of 62 months,
the 5-year survival rate was 83% and the relapse-free rate
was 73% (life table). The most important prognostic factor
was tumour grade. In patients with grade 1 and 2 tumours,
the 5-year survival rate and relapse-free rate was 91% and
76% respectively, while the survival for grade 3 tumour was
60% and 22% respectively (P < 0,05 logrank). There was a
suggestion that patients diagnosed by trans-rectal needle
biopsy did better than those diagnosed by trans-urethral
resection, but this was not statistically significant. Disease
stage did not influence survival. The crude late complication
rate was 10% but this was significantly related to the use of
less than 5 fractions of radiation per week.
A separate group of 13 patients with local disease who had
had failed previous hormonal treatment were not analysed.
Their 5-year survival rate was 19%, which is statistically
significantly worse (P< 0,001 logrank).
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TABLE 11. PATIENT CHARACTERISTICS AND METHOD OF
DIAGNOSIS IN 93 PATIENTS TREATED PRIMARILY WITH
RADIATION
TABLE IV. PATIENT SURVIVAL (LIFE TABLE) AND ITS
RELATIONSHIP TO STAGE, HISTOLOGICAL GRADE AND
METHOD OF DIAGNOSIS
logical examination (61%) and stage B disease (57%). The
diagnosis was made by transurethral resection (TUR) in 68%
and by trans-rectal needle biopsy (TRNB) in 27%. The prostatic
acid phosphatase level was either normal or marginally elevated
in all cases. -
Most patients (71 %) were treated with 5 fractions per week.
The remainder were treated with either 3 or 4 fractions per
week because of limited machine availability (Table Ill).
Megavoltage radiation was used in all patients with either





























No. of Overall Disease-free
patients survival (%) survival (%)
Total 93 83 73
Stage
A2 and B 61 85 74
Cl 32 83 70
Grade
1 and 2 82 91 76
3 11 60 22
Diagnostic method
TRNB 25 87 81
TUR 64 81 69
Relapse
Twelve patients have thus far relapsed, 6 with osseous
metastases, 3 with metastases in the prostate gland and 3 with
metastases in the draining lymph nodes. The median rime to
onset of relapse was 25 months overall, 18 months for osseous
metastases and 36 months for nodal or prostate recurrence.
The relapse rate in patients with stage A2/B and stage C
disease was 11 % and 16% respectively. The relapse rate in
patients with well-differentiated, moderately-differentiated and
poorly-differentiated disease on histological examination was
7%, 14% and 45%, respectively. The latter is statistically
significantly higher (P < 0,001, chi-square test). (These, are
crude figures and the relapse rate will increase with further
follow-up.)
Results Severe frequency















Complications were graded according to Radiation Therapy
and Oncology Group (RTOG) system (Table V). The late
complications and their relationship to the radiation fractiona-
tion used is shown in Table VI. The complication rate in
patients treated with 3 - 4 fractions per week was statistically
significantly higher than those treated with 5 fractions per
week (P < 0,001, chi-square test). The complication rate of
those treated with 3 fractions per week was also statistically
significantly higher than those treated with 5 fractions per
week (P < 0,05).
Patients who had undergone previous therapy
Thirteen patients were treated during 1979 - 1988 after
having had hormonal treatment for more than 2 months before
referral. They had all previously presented to local institutions
















TABLE Ill. FRACTlONATION REGIMENS USED IN RADICAL









Survival rates and local control
The 5-year survival rate was 83% oyerall and the relapse-
free rate 73% (life table) with a median follow-up of 62 months
(range 12 - 106 months). The relationship of survival rate to
prognostic factors is shown in Table IV. The survival rate is
not significantly worse in stage Cl patients compared with
those with stage A2 and stage B disease but is significantly
worse in patients 'with poorly differentiated disease on histo-
logical examination (P < 0,05 logrank). There is a suggestion
that patients diagnosed by TRNB do better than those diag-
nosed by TUR but this is not statistically significant. The local
relapse-free rate is 93%.
The minimum treatment volume consisted of the prostate
plus a minimum 2 cm margin as determined with the help of a
planning cystogram in all cases and planning CT in more
recent years. Individual treatment plans were constructed for
each patient and usually consisted of an anterior portal and
two lateral wedges.
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Conclusions
Thanks are due to Mrs J. Wilmott for collecting the data and
Miss H. Murray for typing the manuscript.
67%, respectively, while the corresponding figures in patients
with C2 disease were 48% and 0%.
In our patients with stage A2 - Cl carcinoma, treated
primarily with radiation, we observed a 5-year survival rate of
83% overall and 73% relapse-free rate at a median follow-up of
62 months. The local relapse-free rate was 93%. This is
comparable to the findings in other studies.
The most imponant prognostic factor in our patients was
tumour grade. In patients with grade 1 and 2 tumours, the
overall 5-year survival and relapse-free rates were 91% and
76%, respectively, while the corresponding figures for patients
with grade 3 disease were 60% and 22%, respectively. Disease
stage in our series did not play a major role. Disease grade was
also the most imponant prognostic factor in the RTOG analysis
of 566 cases. lO Disease stage was not, however, an imponant
prognostic factor in our patients, possibly because only patients
with Cl disease were included. There was a suggestion that
patients diagnosed by TRNB did better than those diagnosed
by TUR. This has been discussed elsewhere. l ! The survival
rate for patients in whom previous hormonal therapy had
failed was statistically significantly worse. Hormonal therapy
for asymptomatic patients with localised disease is not curative
and carmot be recommended. In those patientS who relapse
after hormonal therapy, irradiation is unlikely to be curative
and should be administered primarily with palliative intent.
The overall crude complication rate was 10%. This was
strongly related to the radiation fractionation schedule and was
statistically significantly higher in patients treated with fewer
than 5 fractions per week.
We believe that these results suppon the continued admini-
stration of radical inadiation to selected patients with carcinoma
of the prostate. This would include those who are free from
coexistent medical disease that would impair their lifespan and
with stage A2, B and Cl carcinoma. Poorly-differentiated
disease on histological examination is a relative contraindication.
Deviance from conventional fractionation (5 per week)
resulted in increased complications in this group of patients
who have prolonged survival and is not recommended.
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Complications
Grade 2 Grade 3
No. of
patients
TABLE VI. LATE COMPLICATIONS AND THE CRUDE
COMPLICATION RATE (%) AND THEIR RELATIONSHIP TO





Bladder 93 3 4
Bowel 93 5 6
Fractionationsl
wk
3 11 2 2 36
4 16 2 0 13
5 66 4 0 6
hormonal therapy or they had responded poorly to therapy.
The median age was 67 years (range 48 - 74 years). Stage B
disease was present in 62% and stage Cl in 38%. On histological
examination the disease was well or moderately differentiated
in 77% and poorly differentiated in 23%. The survival rate was
poor, being 59% at 3 years and 19% at 5 years. This was
statistically significantly worse than the patients who had not
had previous hormonal therapy (logrank) at both 3 years (P <
0,05) and also at 5 years (P < 0,001). Grade 2 complications
occurred in 2 patients, giving a crude complication rate of
15%.
Carcinoma of the prostate may have a long natural history yet
progressive disease is a major cause of morbidity and monality
in patients who do not have coexistent medical disorders. It is
the third leading cause of cancer deaths in Western countries.!
There are no published prospective randomised studies com-
paring radical irradiation to no treatment in patients with
localised carcinoma of the prostate as these studies have failed
to accrue sufficient numbers of patients. The critical review of
results of therapy is therefore panicularly imponant.
In an American pattern-of-care study9 of external beam
irradiation for prostate cancer, the results of 682 patients
treated in ~ommunity hospitals were reviewed. These have
been compared with the fmdings of the American College of
Surgeons (ACS) in patients who were treated by hormonal therapy
only or were followed up only.!Q There was a clear benefit in
survival at 5 years in patients treated with irradiation for stage
A disease (85% v. 72%) and stage B disease (75% v. 68%).
Survival was similar in patients with stage C disease (58% and
59%, respectively). It was, however, speculated that any benefit
from honnonal therapy in stage C patients will be exhausted
by 5 years and that there might be increased monality in the
group of patients who had not received radical therapy at
between 5 years and 10 years. The lO-year survival rates in the
American pattern-of-care study8 of irradiation for stage A, B
and C :.iisease were 61%, 46% and 38%, respectively, while
there are no 10-year survival-rate figures available for the ACS
series. In addition, patients with stage C disease were not
divided into stage Cl and C2, which has been shown to be
highly significant in patients treated with external beam ina-
diation.
In a recent study,8 patients with st:;ge Cl disease had an
overall survival and a relapse-free survival rate of 74% and
